Carrie Hersh, DO

5.0144 ratings, 40 reviews

Neuroimmunology

Need help scheduling? Call (702) 483-6000

Highlights

Age Groups Seen

Adult

Languages

English

Gender

Female

About Carrie Hersh

Biography

Carrie M. Hersh, DO, MSc, FAAN joined the faculty at Cleveland Clinic Lou Ruvo Center for Brain Health (CCLRCBH) in August 2015 as a specialist in multiple sclerosis (MS) and neuroimmunology and is Associate Professor of Neurology at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CWRU). At CCLRCBH, she directs the MS Health and Wellness and Professional Engagement programs and is Associate Program Director of the MS and Neuroimmunology Fellowship. She completed a MS fellowship at the Cleveland Clinic Mellen Center through a National MS Society (NMSS) Sylvia Lawry Award. She earned a master’s degree in clinical research through the Clinical Research Scholars Program (CRSP) at CWRU. She completed her adult neurology residency training at Cleveland Clinic and graduated medical school with honors from Nova Southeastern University-College of Osteopathic Medicine. She earned her BS degree in microbiology and neurobiology at University of Florida, graduating summa cum laude, and is a member of Phi Beta Kappa. She is a Fellow of the American Academy of Neurology (AAN) and graduated from the AAN Women Leading in Neurology Program in 2023.

Dr. Hersh’s clinical research interests are in real-world evidence and comparative effectiveness studies. She is the principal investigator of clinical trials and investigator-initiated studies evaluating the effects of MS disease-modifying therapies on clinical, radiographic, and patient-reported outcomes. She also serves on international study steering committees. Dr. Hersh is a frequent lecturer on MS and neuroimmunology topics at national and international meetings, has a prolific publication record in peer-reviewed journals, and has been guest medical editor for MS publications.

Dr. Hersh has special interest in gender equity, professional engagement and development, and burnout prevention among healthcare professionals, for which she has directed national symposia and is published on this topic. She is also an Advanced Peer Coach through the Cleveland Clinic Center of Excellence in Coaching and Mentoring.

Dr. Hersh is Chair of national committees for the Multiple Sclerosis Association of America and Consortium of MS Centers (CMSC). She is also President-Elect of the CMSC Board of Governors Executive Committee. Dr. Hersh is on the AAN Career Leadership Development Subcommittee and Wellness Subcommittee, serves on the NMSS National Medical Advisory Committee, and sits on national and international steering committees, expert panels, and advisory boards.

Request Second Opinion

Get the peace of mind you deserve. When it matters most, you can count on a second opinion from the experts at Cleveland Clinic. Find answers. Feel confident. Get a Second Opinion.

Locations

Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas
- 888 West Bonneville Avenue, Las Vegas, NV 89106
- Get Directions
- phone:
- fax:

Education & Board Certifications

Education

Graduate School: Case Western Reserve University School of Medicine, 2016
Fellowship: Cleveland Clinic, 2015
Residency: Cleveland Clinic, 2013
Internship: Cleveland Clinic, 2010
Medical Education: Nova Southeastern University, 2009
Undergraduate: University of Florida, 2005

Board Certifications

Neurology: American Board of Psychiatry & Neurology, 2013

Professional Highlights

Peer Reviewed Publications:
Hersh, CM. The effects of environmental challenges on nociception/orphanin FQ-induced anxiety. J Undergrad Res. 2005; 6(7). http://ufdc.ufl.edu/UF00091523/00330/1j.
Hersh, C, Rae-Grant, A. Extended-release dalfampridine in the management of MS-related walking impairment. Ther Adv Neurol Disord. 2012; 5(4):199-204. doi: 10.1177/1756285612447091. PMID: 22783369.
Hersh, CM, Cohen, JA. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Immunotherapy. 2014; 6(3): 249-259. doi: 10.2217/imt.14.7. PMID: 24762071.
Hersh, CM, Hara-Cleaver, C, Rudick, RA, Cohen, JA, Bermel, RA, Ontaneda, D. Experience with fingolimod in clinical practice. Int J Neurosci. 2015; 125(9):678-85. doi: 10.3109/00207454.2014.969839. PMID: 25271798.
Hersh, CM, Love, TE, Cohn, S, Hara-Cleaver, C, Bermel, RA, Fox, RJ, Cohen, JA, Ontaneda, D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Mult Scler Relat Disord. 2016 Nov; 10:44-52. doi: 10.1016/j.msard.2016.08.002. PMID: 27919497.
Hersh, CM, John, S, Subei, A, Willis, MA, Kosmorsky, G, Prayson, RA, Bhimraj, A. Optic neuropathy and stroke secondary to invasive Aspergillus in an immunocompetent patient. J Neuroophthalmol. 2016 Dec; 36(4):404-407. doi: 10.1097/WNO.0000000000000361. PMID: 27031126.
Hersh, CM, Love, TE, Bandyopadhyay, A, Cohn, S, Hara-Cleaver, C, Bermel, RA, Fox, RJ, Cohen, JA, Ontaneda, D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Mult Scler J Exp Transl Clin. 2017 Aug; 3(3):2055217317715485. doi: 10.1177/2055217317715485. PMID: 28890796.
Moss, B, Rensel, MR, Hersh, CM. Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics. 2017 Oct; 14(4):999-1017. doi: 10.1007/s13311-017-0563-6. PMID: 28785958.
Vollmer, B, Ontaneda D, Bandyopadhyay, A, Cohn, S, Nair, K, Sillau, S, Bermel, R, Corboy, J, Fox, RJ, Vollmer, T, Cohen, JA, Alvarez, A, Hersh, CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in two centers. Neurol Clin Pract. 2018 Aug; 8(4):292-301. doi: 10.1212/CPJ.0000000000000487. PMID: 30140580.
Hua, LH, Hersh, CM, Morten, P, Kusel, J, Lin, F, Cave, J, Varga, S, Herrera, V, Ko, J. The impact of price reductions after loss of exclusivity in a cost-effective analysis: fingolimod versus intramuscularly-administered interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. J Manag Care Spec Pharm. 2019 Apr; 25(4):490-498. doi: 10.18553/jmcp.2019.25.4.490. PMID: 30917079.
Vollmer, B, Ontaneda, D, Harris, H, Nair, K, Bermel, R, Corboy, J, Fox, RJ, Vollmer, T, Cohen, JA, Alvarez, A, Hersh, CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15; 407:116498. doi:10.1016/j.jns.2019.116498. PMID: 31644992.
Conway, DS, Hersh, CM, Harris, HC, Hua, LH. Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population. Mult Scler J Exp Transl Clin. 2020 Jan 27; 6(1): 2055217320902488. doi: 10.1177/2055217320902488. PMID: 32064117.
Hua, LH, Harris, H, Conway, D, Hersh, CM. Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy. J Neurol. 2020 Aug;267(8):2214-2220. doi: 10.1007/s00415-020-09816-1. PMID: 32270292.
Ontaneda, D, Tallantyre, EC, Raza, PC, Planchon, S, Nakamura, K, Miller, D, Hersh, C, Craner, M, Bale, C, Chaudhry, B, Gunzler, DD, Love, TE, Gerry, S, Coles, A, Cohen, JA, Evangelou, N. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemp Clin Trials. 2020 Aug;95:106009. doi: 10.1016/j.cct.2020.106009. PMID: 32320842.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups and Clinical Investigators: Hersh, C (I did not work closely with any of the listed authors on this publication). Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246.N Engl J Med. 2020. PMID: 32757523.
Mowry, E, Bermel, RA, Williams, JR, Benzinger, T, de Moor, C, Fisher, E, Hersh, CM, Hyland, MH, Izbudak, I, Jones, SE, Kieseier, BC, Kitzler HH, Krupp, L, Lui, YW, Montalban, X, Naismith, RT, Nicholas,, JA, Pellegrini, F, Rovira, A, Schulze, M, Tackenberg, B, Tintore, M, Tivarus, ME, Ziemssen, T, Rudick, RA. Harnessing real-world data to inform decision-making: multiple sclerosis partners advancing technology and health solutions (MS PATHS). Front Neurol. 2020 Aug 7;11:632. doi: 10.3389/fneur.2020.00632. PMID: 32849170.
Hersh, CM, Harris, H, Ayers, M, Conway, D. Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod. Mult Scler J Exp Transl Clin. 2020 Oct 13;6(4):2055217320959815. doi: 10.1177/2055217320959815. PMID: 33110616.
Hua, LH, Hersh, CM, Tian, F, Mowry, EM, Fitzgerald, KC. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60. Mult Scler Relat Disord. 2020 Nov 23;47:102637. doi: 10.1016/j.msard.2020.102637. PMID: 33276238.
Hersh, CM, Harris, H, Conway, D, Hua, LH. Impact of switching from natalizumab to moderate versus high efficacy DMT in clinical practice. Neurol Clin Pract. 2020 Dec 10 (6) e53-e65; doi: 10.1212/CPJ.0000000000000809. PMID: 33510948. Received “Notable This Week” and “Most Read Article” designations.
Morrison-Banks, E, Michtich, K, Hersh, CM. How the COVID-19 pandemic has changed multiple sclerosis clinical practice: results of a nationwide provider survey. Mult Scler Relat Disord. 2021 Mar 18;51:102913. doi: 10.1016/j.msard.2021.102913. PMID: 33839482.
Hersh, CM, Brook, RA, Beren, IA, Rohrbacker, NJ, Lebson, L, Henke, C, Phillips, A. The implications of suboptimal treatment outcomes with disease-modifying drugs in employees with multiple sclerosis. J Med Econ. 2021 Mar 19;24:1:479-486.doi: 10.1080/13696998.2021.1906013. PMID: 33739915.
Hersh, CM, Kieseier, B, deMoor, C, Miller, D, Campagnolo, D, Williams, JR, Fitzgerald, K, Xiong, K, McGinley, M, Hyland, M, Ruddick, R, Ziemssen, T, Koulinska, I. Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: results of MS PATHS. 2021 Apr 15;7(2). doi: 10.1177/20552173211004634.
Ziemssen, T, Giovannoni, G, Alvarez, E, Bhan, V, Hersh, C, Hoffman, O, Oreja-Guevara, C, Robles-Cedeno, R, Trojano, M, Vermersch, P, Dobay, P, Khwaja, M, Stadler, B, Rauser, B, Hach, T, Piani-Meier, D, Burton, J. MSProDiscussTM, a useful digital tool to evaluate early signs of multiple sclerosis disease progression in a real world setting. J Med Internet Res. J Med Internet Res. 2021 Oct 6;23(10):e29558. doi: 10.2196/29558. PMID: 34612826.
Cohen, JA, Bermel, RA, Grossman, CI, Hersh, CM, Hyland, H, Mowry, EM, Naismith, R, Naylor, ML, Nicholas, J, Rajbhandari, R, Singh, CM, Tintorè, M, Zabalza, A, Ziemssen, T, Williams, JR, Montalban, X, on behalf of the MS PATHS Investigators. IgG Immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within MS PATHS. Mult Scler. 2022 Jan 7;13524585211061343. doi: 10.1177/13524585211061343. PMID: 34994577.
Hersh, CM, Altincatal, A, Kapadia, S, de Moor, C, Rudick, R, Williams, JR, Miller, C, Koulinska, I. Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics. Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. PMID: 35024161.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial: Hersh, CM. Lancet Neurol. 2022 Apr 25:S1474-4422(22)00143-0. doi: 10.1016/S1474-4422(22)00143-0. Epub ahead of print. PMID: 35483387.
Conway DS, Briggs FB, Mowry EM, Fitzgerald KC, Hersh, CM. Racial disparities in hypertension management among multiple sclerosis patients. Mult Scler Relat Disord. 2022 Jun 15;64:103972. doi: 10.1016/j.msard.2022.103972. Epub ahead of print. PMID: 35728435.
Amin, M and Hersh, CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag. 2022 Oct 31. doi: 10.2217/nmt-2021-0058. Epub ahead of print. PMID: 36314777.
Sotirchos, ES, Fitzgerald, KC, Singh, CM, Smith, MD, Reyes-Mantilla, M, Hersh, CM, Hyland, MH, Canissario, R, Simmons, S, Arrambide, G, Montalban, X, Comabella, M, Naismith, RT, Krupp, LB, Nicholas, JA, Ziemssen, T, Rudick, R, Fisher, E, Bermel, RA, Mowry, EM, Calabresi, PA. Associations of serum neurofilament light chain with clinical characteristics and radiological measures in a large real world MS population. Ann Clin Transl Neurol. 2022 Nov 25. doi: 10.1002/acn3.51704. Epub ahead of print. PMID: 36427295.
Sullivan, AB, Hersh, CM, Rensel, R, Benzil, D. Leadership inequity, burnout and lower engagement of women in medicine. J Health Serv Psychol. 2023. https://doi.org/10.1007/s42843-023-00078-9.
Hersh, CM, Morrow, SA, Williams, MJ, Amezcua, L, Halper, J, Wandersee, K. Diversity, Equity, and Inclusion in the Multiple Sclerosis Community: A Call to Action. Int J MS Care. 2023 May 23. https://doi.org/10.7224/1537-2073.2023-039.
Sotirchos, ES, Hu, C, Smith, MD, Lord, H, DuVal, A, Arrambide, G, Montalban, X, Akguen, K, Ziemssen, T, Naismith, RT, Hersh, CM, Hyland, MH, Krupp, LB, Nicholas, JA, Bermel, RA, Mowry, EM, Calabresi, PA, Fitzgerald, KC. Agreement between reference resources for blood neurofilament light chain levels in people with multiple sclerosis. Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957. doi: 10.1212/WNL.0000000000207957. Epub ahead of print. PMID: 37816633.
Alvarez, E, Longbrake, EE, Rammohan, K, Stankiewicz, J, Hersh, CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023 Sep 15;79:105009. doi: 10.1016/j.msard.2023.105009. Epub ahead of print. PMID: 37783194.
Hersh, CM. Contemporary topics in multiple sclerosis. Neurol Clin. 2024 Feb;42(1):xiii-xv. doi: 10.1016/j.ncl.2023.08.001. Epub 2023 Aug 26. PMID: 37980125.
Aboseif, A, Roos, I, Krieger, S, Kalincik, T, Hersh, CM. Leveraging real world evidence and observational studies in treating multiple sclerosis. Neurol Clin. 2024 Feb;42(1):203-227. doi: 10.1016/j.ncl.2023.06.003. Epub 2023 Jul 21. PMID: 37980116.
Hersh, CM, Morrow, SA, Williams, MJ, Amezcua, L, Halper, J, Wandersee, K. Diversity, Equity, and Inclusion in the Multiple Sclerosis Community: A Call to Action. Int J MS Care. 2023 Sep-Oct;25(5):199-205. doi: 10.7224/1537-2073.2023-039. Epub 2023 Sep 14. PMID: 37720263; PMCID: PMC10503818.
Alvarez, E, Longbrake, EE, Rammohan, K, Stankiewicz, J, Hersh, CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023 Nov;79:105009. doi: 10.1016/j.msard.2023.105009. Epub 2023 Sep 15. PMID: 37783194.
Sotirchos, ES, Hu, C, Smith, MD, Lord, H, DuVal, A, Arrambide, G, Montalban, X, Akguen, K, Ziemssen, T, Naismith, RT, Hersh, CM, Hyland, MH, Krupp, LB, Nicholas, JA, Bermel, RA, Mowry, EM, Calabresi, PA, Fitzgerald, KC. Agreement between reference resources for blood neurofilament light chain levels in people with multiple sclerosis. Neurology. 2023 Dec 4;101(23):e2448-e2453. doi: 10.1212/WNL.0000000000207957. PMID: 37816633.
Krieger, S, Cook, K, Hersh, CM. Understanding multiple sclerosis as a disease spectrum: Above and below the clinical threshold. Curr Opin Neurol. 2024 Jun 1;37(3):189-201. doi: 10.1097/WCO.0000000000001262. Epub 2024 Apr 9. PMID: 38535979; PMCID: PMC11064902.
Hersh, CM, Pang, M, Miller, DM, McGinley, MP, Hyland, M, Ziemssen, T, Avila, RL. Comparison of time to clinically meaningful improvement in Neuro-QoL in patients treated with natalizumab vs ocrelizumab. Neurodegener Dis Manag. 2024;14(2):21-33. doi: 10.2217/nmt-2023-0047. Epub 2024 Apr 16. PMID: 38623894.
Hersh, CM, Sun, Z, Conway, DS, Sotirchos, E, Fitzgerald, KC, Hua, LH, Ziemssen, T, Naismith, RT, Pellegrini, F, Grossman, C, Campbell, N. A 2-Stage Model of Heterogenous Treatment Effects for Brain Atrophy in Multiple Sclerosis Utilizing the MS PATHS Research Network. Mult Scler Relat Disord. 2024 Sep 2;91:105847. doi: 10.1016/j.msard.2024.105847. Epub ahead of print. PMID: 39260226.
Hersh, CM, Gorritz, M, Chen, C, Tuly, R, Gu, Y, Gadkari, A, Brown, B, Shao, Q. Real-world persistence and adherence of ofatumumab versus oral and injectable disease modifying therapies in patients with multiple sclerosis. Mult Scler Relat Disord. 2024 Nov;91:105888. doi: 10.1016/j.msard.2024.105888. Epub 2024 Sep 12. PMID: 39388747.
Conway, DS, Toljan, K, Harris, K, Galioto, R, Briggs, FBS, Hersh, CM. Body Mass Index Trends Over Four Years in Persons with Multiple Sclerosis. Mult Scler Relat Disord. 2024 Dec 8;93:106218. doi: 10.1016/j.msard.2024.106218. Epub ahead of print. PMID: 39667128.
Briggs, FB, Conway, DS, Hersh, CM, Fitzgerald, K, Mowry, E, Cohen, JA, Ontaneda, D. The onset of multiple sclerosis differs in Hispanic/Latinx Americans compared to non-Hispanic White Americans. Mult Scler. 2024 Dec 24:13524585241304976. doi: 10.1177/13524585241304976. Epub ahead of print. PMID: 39718152.
Aboseif, A, Orme, D, Chitnis, T, Hersh, CM. Utilizing Heterogeneous Treatment Effects in Pursuit of Personalized Multiple Sclerosis Care. Practical Neurology. 01/2025.
Amin, M, Harvey, T, Pineda, DM, Moss, B, Tai, M, Gadkari, A, Brown, B, Conway, DS, Hersh, CM. Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice. Accepted for publication: Neurodegener Dis Manag. 01/2025.

Awards

2001 University of Florida Honors Program
2002 Phi Eta Sigma Honor Society, UF
2002 National Society of Collegiate Scholars
2002 Golden Key International Honor Society, UF
2004 National Dean’s List
2004 National Society of Collegiate Scholars Merit Award, UF
2004 Presidential Recognition, UF
2004 Chancellor’s List, UF
2004 University Scholars Program, UF
2004 Phi Kappa Phi Honor Society, UF
2004 Phi Beta Kappa, UF
2005-2009 Dean’s List, NSU
2006 Sigma Sigma Phi Honor Society, NSU
2009 Psi Sigma Alpha National Osteopathic Honor Society, NSU
2012 7th Annual MASTER MS Fellowship Program
2014 Consortium of MS Centers (CMSC) Scholarship Award
2015 American Academy of Neurology (AAN) Fellows Scholarship Award
2015 Neurological Institute Research Day Clinical Fellow Award, CCF
2016 Travel Grant Award, European Committee for Treatment and Research in MS (ECTRIMS) 2016
2016 Top Score Poster, ECTRIMS 2016
2016 Editor’s Choice for original research, Multiple Sclerosis and Related Disorders journal article “Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up”
2017 Travel Grant Award, ECTRIMS 2017
2018 Healthcare Headliner Award in Research/Science, Vegas Inc.
2018 Top Score Poster, ECTRIMS 2018
2019 Top Score Poster, ECTRIMS 2019
2020 Fellow of the American Academy of Neurology (FAAN)
2023 Graduate of AAN Women Leading in Neurology Program
2023 and 2024 Most Read and Cited Articles , Multiple Sclerosis and Related Disorders and Neurodegenerative Disease Management peer-reviewed journals

Professional Memberships

Consortium of Multiple Sclerosis Centers; National Multiple Sclerosis Society; Multiple Sclerosis Association of America; American Academy of Neurology

Research & Publications

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2025-12-08, Dr. Hersh has reported the financial relationships with the companies listed below.

Consulting and/or Speaking. Dr. Hersh receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

TG Therapeutics, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Insurances Accepted

Review a list of accepted insurance plans for our Nevada locations or learn more about purchasing a contracted managed care plan.

Video

Ratings & Reviews

5 out of 5

144 ratings, 40 reviews

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Explains

Courtesy Respect & Concern

Patient Rating of Doctor

Search reviews

Search Reviews

5 out of 5 stars
Reviewed on 4/27/2026
Dr. Hirsch was so warm and caring.
5 out of 5 stars
Reviewed on 4/27/2026
I absolutely love Dr Herch.
5 out of 5 stars
Reviewed on 4/6/2026
Dr. Hersh was extremely thorough and provided information that I had not received from my Neurologist Dr. YU for the seven years that I was his patient.
5 out of 5 stars
Reviewed on 4/6/2026
Dr Hersch is hands down the best
5 out of 5 stars
Reviewed on 4/6/2026
Dr. Hersh demonstrated exceptional knowledge regarding Multiple Sclerosis. I was impressed by her knowledge and care.
5 out of 5 stars
Reviewed on 3/12/2026
Dr Hersh is absolutely the best care provider and doctor I''ve ever had! Thank you!
5 out of 5 stars
Reviewed on 3/5/2026
Very compassionate and skilled doctor
5 out of 5 stars
Reviewed on 2/12/2026
Dr. Hersh is awesome. We feel blessed to work with her with our daughter.
5 out of 5 stars
Reviewed on 1/26/2026
I recommend Dr. Hersh frequently. She is the best.
5 out of 5 stars
Reviewed on 1/26/2026
Dr. Hersh is wonderful. She always spends time listening and explaining things.
5 out of 5 stars
Reviewed on 1/26/2026
Dr.Hersch was very kind and seemed very knowledgeable. She was very throuugh and very professional. Thank you.
5 out of 5 stars
Reviewed on 1/14/2026
The best staff and doctors by far
5 out of 5 stars
Reviewed on 1/9/2026
Starting a new life long journey with a doctor makes you hope for a good one. My first doctor was not a good one. I feel so much better about my doctor/patient relationship after our very first visit.
5 out of 5 stars
Reviewed on 11/7/2025
Dr. Hersh exceeded my expectations. I am sincerely grateful for the appointment and the time she spent with me.
5 out of 5 stars
Reviewed on 11/4/2025
Dr Hersh is an excellent doctor She is an asset to your team
5 out of 5 stars
Reviewed on 11/4/2025
Awesome experience I look forward to continuing my Care with Dr. Hersh
5 out of 5 stars
Reviewed on 10/16/2025
Dr Carrie M Hersh was amazing, she was extremely knowledgeable and thorough. She corrected an incorrect diagnosis and gave me a proper diagnosis and route to go for treatment. She was very caring while doing the test for my situation and explained everything clearly and wanted to make sure I understood what she was explaining. I truly valued her expertise and compassion, I wish more doctors were like her. I have several very serious and life threatening disorders and she cared for my situation with an earnest compassion I have rarely seen in a doctor. She is without a doubt a valuable colleague for your medical practice and an example that more doctors should strive to imitate.
5 out of 5 stars
Reviewed on 10/7/2025
She is genuinely caring, knowledge, and respectful
5 out of 5 stars
Reviewed on 9/22/2025
I was blown away by Dr. Carrie Hersh and her kindness, professionalism, and care. She was absolutely incredible.
5 out of 5 stars
Reviewed on 9/22/2025
This was my first time meeting Dr. Hersh, very pleasant, knowledgeable and listened to me. She asked questions that was pertinent to my health and past care.
5 out of 5 stars
Reviewed on 9/8/2025
I have had MS for over 25 years and Dr. Hersh is BY FAR the best neurologist I have ever had! Congratulations to you for having her on your team
5 out of 5 stars
Reviewed on 9/8/2025
Dr. Hersh took the time to know how I feel before suggesting a treatment for me
5 out of 5 stars
Reviewed on 9/8/2025
Best provider I have ever had! Best clinic I have ever been to, all staff are amazing, kind, professional.
5 out of 5 stars
Reviewed on 9/8/2025
Best provider I have ever had, I trust her completely
5 out of 5 stars
Reviewed on 9/8/2025
Dr Hersch and staff are always exceptional. The greeting, the smile and the show of true compassion is worth the drive to get to the visit.
5 out of 5 stars
Reviewed on 8/27/2025
It is as good as seeing family when I get to visit Dr Hersh. She is a True healer who puts her passion into all she does. She is super thorough and courteous. Just can't beat the excellent experiences I've had since going to her. I would recommend her any time any where any place to anyone who will listen.
5 out of 5 stars
Reviewed on 8/27/2025
Dr.Hersh is an excellent doctor! She had a visiting doctor shadowing her during my appointment. Both doctors were good and all of my questions were answered . I am thrilled that Dr. Carrie Hersh is the doctor that has helped me through my M.S.
5 out of 5 stars
Reviewed on 8/27/2025
If I could give a 10 out of 5 I would! I have never received care like I do from Dr. Hersh. She truly cares and it shows. Even though she doesn't have all of the answers and I am not the typical case she would see, she finds the answers she does not know and is very good at helping my husband and I understand what is going on. I could not be happier with my care.
5 out of 5 stars
Reviewed on 8/27/2025
She's always the best.. I can't ask her anything better besides to say she's the best and is always professional and very Thorough in everything she does and very knowledgeable and helpful.. Wi anything she can do to enhance my life.. I needed a Walker and she went above and beyond to make sure I was taking care of.. I won't ever forget that as I really appreciate it..although it wasn't brought up.. At the time of my visit
5 out of 5 stars
Reviewed on 8/27/2025
I've trusted this facility and Dr. Hersh fully as I've navigated through my life with M.S.
5 out of 5 stars
Reviewed on 8/20/2025
The very best doctor I've ever had! Dr Hersh truly cares and provides the absolute best care!
5 out of 5 stars
Reviewed on 8/20/2025
Dr. Hersh is excellent. I'm very grateful for her and Cleveland Clinic.
5 out of 5 stars
Reviewed on 8/11/2025
Dr. Hersh was thorough in her examination and demonstrated a professional, caring attitude throughout the appointment. I enjoyed meeting her and felt comfortable and at ease when discussion my medical history and symptoms of MS. She came recommended, and now I understand why.
5 out of 5 stars
Reviewed on 7/22/2025
Dr. Hersh is very through, explained things clearly in laymen's terms and made me feel very comfortable. I would highly recommend her.
5 out of 5 stars
Reviewed on 7/22/2025
Dr. Hirsh is the best!!!
5 out of 5 stars
Reviewed on 7/15/2025
Dr Hersch spent 1.5 hours with me on my 1st visit. I thought she was knowledgeable, shared info with me & prompted a plan for MS with me.
5 out of 5 stars
Reviewed on 6/10/2025
Dr. Hersh is the only doctor I've seen who genuinely cares about her patients.
5 out of 5 stars
Reviewed on 5/12/2025
Dr.Hersh is great with a lovely smile
5 out of 5 stars
Reviewed on 5/12/2025
Dr Hersh is professional, knowledgeable and caring
5 out of 5 stars
Reviewed on 5/4/2025
Dr Hersh is excellent!